Figure 2From: A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients Final assessment of 6-monthly leuprolide acetate therapy by the participating urologists. Legend. Diagnosis and treatment decisions were at the sole discretion of the treating physicians. The physicians stated that the most frequent reasons for choosing 6-monthly leuprolide acetate were the long dosage interval, small injection volume, and short cannula. Less frequent reasons for choosing 6-monthly leuprolide acetate included compliance/patient's request, costs, physician's interest in 6-monthly leuprolide acetate, and good efficacy of the Astellas leuprolide acetate. Other reasons were named in minor frequencies.Back to article page